Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune Responses.

Autor: Huang Y; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Department of Biostatistics, University of Washington, Seattle, WA 98195, USA., Alam S; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Andersen-Nissen E; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Cape Town HVTN Immunology Laboratory, Cape Town 8001, South Africa., Carpp LN; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Dintwe OB; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Cape Town HVTN Immunology Laboratory, Cape Town 8001, South Africa., Flach BS; Cape Town HVTN Immunology Laboratory, Cape Town 8001, South Africa., Grunenberg N; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., Laher F; Perinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Soweto, Johannesburg 2193, South Africa., De Rosa SC; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195, USA., Ferrari G; Department of Surgery, Duke University, Durham, NC 27705, USA.; Duke Human Vaccine Institute, Durham, NC 27710, USA.; Center for Human Systems Immunology, Durham, NC 27701, USA., Innes C; The Aurum Institute, Klerksdorp 2570, South Africa., Bekker LG; The Desmond Tutu HIV Centre, University of Cape Town, Cape Town 7925, South Africa., Kublin JG; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA., McElrath MJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Department of Medicine, University of Washington, Seattle, WA 98195, USA., Tomaras GD; Department of Surgery, Duke University, Durham, NC 27705, USA.; Duke Human Vaccine Institute, Durham, NC 27710, USA.; Center for Human Systems Immunology, Durham, NC 27701, USA.; Department of Integrative Immunobiology, Duke University Medical Center, Durham, NC 27710, USA.; Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27710, USA., Gray GE; South African Medical Research Council, Cape Town 7460, South Africa., Gilbert PB; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Department of Biostatistics, University of Washington, Seattle, WA 98195, USA.

Publikováno v: Viruses [Viruses] 2024 Aug 27; Vol. 16 (9). Date of Electronic Publication: 2024 Aug 27.

Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.

Autor: Moodie Z; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Andersen-Nissen E; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.; Cape Town HVTN Immunology Laboratory, Hutchinson Centre Research Institute of South Africa, Cape Town, South Africa., Grunenberg N; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Dintwe OB; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.; Cape Town HVTN Immunology Laboratory, Hutchinson Centre Research Institute of South Africa, Cape Town, South Africa., Omar FL; Cape Town HVTN Immunology Laboratory, Hutchinson Centre Research Institute of South Africa, Cape Town, South Africa., Kee JJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Bekker LG; Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa., Laher F; Perinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa., Naicker N; Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa; and Department of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa., Jani I; Instituto Nacional de Saude, Maputo, Mozambique., Mgodi NM; Clinical Trials Research Centre, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe., Hunidzarira P; Clinical Trials Research Centre, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe., Sebe M; Aurum Institute, Tembisa, Gauteng, South Africa., Miner MD; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Polakowski L; DAIDS, NIAID, NIH, Bethesda, Maryland, United States of America., Ramirez S; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Nebergall M; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Takuva S; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Sikhosana L; Hutchinson Centre Research Institute of South Africa, Johannesburg, South Africa., Heptinstall J; Department of Surgery, Duke University, Durham, North Carolina, United States of America., Seaton KE; Department of Surgery, Duke University, Durham, North Carolina, United States of America., De Rosa S; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Diazgranados CA; Formerly Sanofi-Pasteur, Swiftwater, Pennsylvania, Pennsylvania, United States of America., Koutsoukos M; GSK, Wavre, Belgium., Van Der Meeren O; Previously GSK, Rixensart, Belgium., Barnett SW; Bill & Melinda Gates Foundation, Seattle, Washington, United States of America., Kanesa-Thasan N; Formerly GSK, Rockville, Maryland, United States of America., Kublin JG; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Tomaras GD; Department of Surgery, Duke University, Durham, North Carolina, United States of America., McElrath MJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Corey L; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America., Mngadi K; Aurum Institute, Tembisa, Gauteng, South Africa., Goepfert P; Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.

Publikováno v: PLoS medicine [PLoS Med] 2024 Mar 19; Vol. 21 (3), pp. e1004360. Date of Electronic Publication: 2024 Mar 19 (Print Publication: 2024).

Immune profiling of Mycobacterium tuberculosis-specific T cells in recent and remote infection.

Autor: Mpande CAM; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, South Africa., Rozot V; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, South Africa., Mosito B; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, South Africa., Musvosvi M; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, South Africa., Dintwe OB; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, South Africa., Bilek N; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, South Africa., Hatherill M; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, South Africa., Scriba TJ; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, South Africa., Nemes E; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, South Africa. Electronic address: elisa.nemes@uct.ac.za.

Publikováno v: EBioMedicine [EBioMedicine] 2021 Feb; Vol. 64, pp. 103233. Date of Electronic Publication: 2021 Feb 18.

A randomized clinical trial in adults and newborns in South Africa to compare the safety and immunogenicity of bacille Calmette-Guérin (BCG) vaccine administration via a disposable-syringe jet injector to conventional technique with needle and syringe.

Autor: Geldenhuys HD; South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine (IDM) and Department of Paediatrics and Child Health, University of Cape Town, Brewelskloof Hospital, Haarlem Street, Worcester 6850, South Africa. Electronic address: hennie.geldenhuys@uct.ac.za., Mearns H; South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine (IDM) and Department of Paediatrics and Child Health, University of Cape Town, Brewelskloof Hospital, Haarlem Street, Worcester 6850, South Africa., Foster J; PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98109, USA., Saxon E; PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98109, USA., Kagina B; Vaccine for Africa Initiative (VACFA), Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, Anzio Road, Observatory 7925, Cape Town, South Africa., Saganic L; PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98109, USA., Jarrahian C; PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98109, USA., Tameris MD; South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine (IDM) and Department of Paediatrics and Child Health, University of Cape Town, Brewelskloof Hospital, Haarlem Street, Worcester 6850, South Africa., Dintwe OB; South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine (IDM) and Department of Paediatrics and Child Health, University of Cape Town, Brewelskloof Hospital, Haarlem Street, Worcester 6850, South Africa., Van Rooyen M; South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine (IDM) and Department of Paediatrics and Child Health, University of Cape Town, Brewelskloof Hospital, Haarlem Street, Worcester 6850, South Africa., Luabeya KK; South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine (IDM) and Department of Paediatrics and Child Health, University of Cape Town, Brewelskloof Hospital, Haarlem Street, Worcester 6850, South Africa., Hussey G; Vaccine for Africa Initiative (VACFA), Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, Anzio Road, Observatory 7925, Cape Town, South Africa., Scriba TJ; South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine (IDM) and Department of Paediatrics and Child Health, University of Cape Town, Brewelskloof Hospital, Haarlem Street, Worcester 6850, South Africa., Hatherill M; South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine (IDM) and Department of Paediatrics and Child Health, University of Cape Town, Brewelskloof Hospital, Haarlem Street, Worcester 6850, South Africa., Zehrung D; PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98109, USA.

Publikováno v: Vaccine [Vaccine] 2015 Sep 08; Vol. 33 (37), pp. 4719-26. Date of Electronic Publication: 2015 Apr 07.

Varicella zoster-specific CD4+Foxp3+ T cells accumulate after cutaneous antigen challenge in humans.

Autor: Vukmanovic-Stejic M; Division of Infection and Immunity, University College London, London W1T 4JF, United Kingdom., Sandhu D, Sobande TO, Agius E, Lacy KE, Riddell N, Montez S, Dintwe OB, Scriba TJ, Breuer J, Nikolich-Zugich J, Ogg G, Rustin MH, Akbar AN

Publikováno v: Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2013 Feb 01; Vol. 190 (3), pp. 977-86. Date of Electronic Publication: 2013 Jan 02.